Clinical Trial Update: Folinic Acid for Prevention of Pemetrexed-induced Toxicity [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating folinic acid to prevent pemetrexed-induced toxicity in NSCLC, mesothelioma, and thymoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer
• Thymoma

Drugs mentioned

• Folinic acid (folinic acid)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Amphia Hospital | Conditions: NSCLC, Mesothelioma | Phase 4 | Status: UNKNOWN